Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1189495

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1189495

Global G-CSF PEG-G-CSF Market - Industry Trends and Forecast to 2030

PUBLISHED:
PAGES: 409 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 4800
PDF (Enterprise License) - Printable/Downloadable
USD 7000

Add to Cart

Global G-CSF/ PEG-G-CSF market is projected to register a substantial CAGR of 5.5% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Global G-CSF/PEG-G-CSF Market, By Indication (Neutropenia, Oncology, Chronic and Autoimmune Disease, Blood Disorders, Growth Harmony Deficiency and Others), Dosage (Mono and Combination), Route Of Administration (Intravenous, Subcutaneous), Packaging (Single Use Vials and Pre Filled Syringes), End User (Hospitals and Clinics, Research and Academic Institutes, Ambulatory Surgical Centers and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy and Others), Country (Mexico, Columbia, Brazil, Argentina, Chile, Peru, Ecuador, Rest of LATAM, Germany, U.K., France, Italy, Russia, Netherlands, Spain, Sweden, Poland, Belgium, Switzerland, Denmark, Norway, Finland, Turkey, Rest of Europe, China, Japan, India, Australia, New Zealand, Indonesia, Thailand, Vietnam, Singapore, Philippines, Malaysia, Rest of Asia-Pacific, South Africa, Saudi Arabia, Egypt, Israel, UAE, Kuwait, Oman, and Rest of Middle East and Africa) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the global G-CSF/PEG-G-CSF market are:

Growing incidences of blood cancers and cancer diseases

Increasing cases of febrile neutropenia

Market Players:

The key market players operating in the global G-CSF/PEG-G-CSF market are listed below:

Lupin

Gennova Biopharmaceuticals Limited

Reliance Life Sciences

Intas Pharmaceuticals Ltd.

BIOSIDUS

Kashiv BioSciences, LLC.

STADA Arzneimittel AG

USV Private Limited

Viatris Inc.

Biocon

Fresenius Kabi AG

Hangzhou Jiuyuan Gene Engineering Co., Ltd.

Amgen Inc.

Pfizer Inc.

Sandoz International GmbH

Apotex Inc.

Cadila Pharmaceuticals

Dr. Reddy's Laboratories Ltd.

Amneal Pharmaceuticals LLC.

Coherus BioSciences

Accord Healthcare

NAPP PHARMACEUTICALS LIMITED.

Intas Pharmaceuticals Ltd.

Mundipharma International

Teva Pharmaceutical Industries Ltd.

Spectrum Pharmaceuticals, Inc.

Kyowa Kirin Co., Ltd.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

TABLE OF CONTENTS

1 INTRODUCTION 51

  • 1.1 OBJECTIVES OF THE STUDY 51
  • 1.2 MARKET DEFINITION 51
  • 1.3 OVERVIEW OF GLOBAL G-CSF / PEG-G-CSF MARKET 51
  • 1.4 LIMITATIONS 53
  • 1.5 MARKETS COVERED 53

2 MARKET SEGMENTATION 56

  • 2.1 MARKETS COVERED 56
  • 2.2 GEOGRAPHICAL SCOPE 57
  • 2.3 YEARS CONSIDERED FOR THE STUDY 58
  • 2.4 CURRENCY AND PRICING 58
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 59
  • 2.6 MULTIVARIATE MODELLING 62
  • 2.7 TYPE LIFELINE CURVE 62
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 63
  • 2.9 DBMR MARKET POSITION GRID 64
  • 2.10 MARKET END USER COVERAGE GRID 65
  • 2.11 VENDOR SHARE ANALYSIS 66
  • 2.12 SECONDARY SOURCES 67
  • 2.13 ASSUMPTIONS 67

3 EXECUTIVE SUMMARY 68

4 PREMIUM INSIGHTS 71

  • 4.1 PESTEL ANALYSIS 74
  • 4.2 PORTER'S FIVE FORCES 75
  • 4.3 GLOBAL G-CSF/PEG-G-CSF MARKET: MERGERS AND ACQUISITION 76
  • 4.4 GLOBAL G-CSF / PEG-G-CSF MARKET 77
  • 4.5 STRATEGIES TO THE ENTER THE MARKET 77
    • 4.5.1 JOINT VENTURE (PARTNERSHIPS): 77
    • 4.5.2 ACQUISITION: 77
    • 4.5.3 LINE EXPANSION VIA COLLABORATION: 77
    • 4.5.4 PRODUCT APPROVAL: 78
    • 4.5.5 PRODUCT LAUNCH: 78
    • 4.5.6 GEOGRAPHIC EXPANSION: 78
    • 4.5.7 COST LEADERSHIP: 79
    • 4.5.8 PRODUCT DEVELOPMENT: 79
  • 4.6 GLOBAL G-CSF / PEG-G-CSF MARKET, INDUSTRY INSIGHTS 80
    • 4.6.1 PATENT ANALYSIS 80
    • 4.6.2 DRUG TREATMENT RATE BY MATURED MARKETS 81
    • 4.6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 81
    • 4.6.4 THERAPEUTIC ASSESSMENT 81
    • 4.6.5 KEY PRICING STRATEGIES 82
    • 4.6.6 KEY PATIENT ENROLLMENT STRATEGIES 82
    • 4.6.7 CONCLUSION 82
  • 4.7 PIPELINE ANALYSIS FOR GLOBAL G-CSF / PEG-G-CSF MARKET 83

5 EPIDEMIOLOGY 84

6 GLOBAL G-CSF / PEG-G-CSF MARKET: REGULATIONS 87

7 MARKET OVERVIEW 90

  • 7.1 DRIVERS 92
    • 7.1.1 GROWING INCIDENCES OF BLOOD CANCERS AND CANCER DISEASES 92
    • 7.1.2 RISING INCIDENCES OF AUTOIMMUNE DISORDERS 93
    • 7.1.3 INCREASING CASES OF FEBRILE NEUTROPENIA 94
    • 7.1.4 INCREASING AWARENESS ABOUT FILGRASTIM AND PEGFILGRASTIM 95
  • 7.2 RESTRAIN 96
    • 7.2.1 STRINGENT GOVERNMENTAL REGULATIONS 96
    • 7.2.2 AVAILABILITY OF ALTERNATIVES FOR THE CHEMOTHERAPY 97
  • 7.3 OPPORTUNITIES 98
    • 7.3.1 THE USE OF BIOSIMILARS HELPS REDUCE HEALTHCARE COSTS FOR PATIENTS 98
    • 7.3.2 COST-EFFECTIVENESS AND PATENT EXPIRY OF BIOLOGICAL PRODUCTS 98
  • 7.4 CHALLENGES 99
    • 7.4.1 THE HIGH COST ASSOCIATED WITH BRANDED BIOLOGICS AND IMPROVED CHEMOTHERAPY 99
    • 7.4.2 THE MULTIPLE SIDE EFFECTS OF G-CSF 99

8 GLOBAL G-CSF/ PEG-G-CSF MARKET, BY INDICATION 100

  • 8.1 OVERVIEW 101
  • 8.2 NEUTROPENIA 105
    • 8.2.1 CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (MYELOSUPPRESSIVE CHEMOTHERAPY TREATMENT) 106
    • 8.2.2 SEVERE CHRONIC NEUTROPENIA 106
    • 8.2.3 RADIOTHERAPY INDUCED NEUTROPENIA 106
    • 8.2.4 NEUTROPENIA IN HIV PATIENTS 106
    • 8.2.5 CLOZAPINE INDUCED NEUTROPENIA 106
    • 8.2.6 NEUTROPENIA IN HEPATITIS C PATIENTS 106
    • 8.2.7 CONGENITAL NEUTROPENIA 106
  • 8.3 ONCOLOGY 107
    • 8.3.1 ACUTE MYELOID LEUKEMIA RECEIVING CONSOLIDATION CHEMOTHERAPY 107
    • 8.3.2 OTHERS 108
  • 8.4 CHRONIC AND AUTO IMMUNE DISEASES 108
  • 8.5 BLOOD DISORDERS 108
  • 8.6 GROWTH HORMONE DEFICIENCY 109
  • 8.7 OTHERS 110

9 GLOBAL G-CSF/ PEG-G-CSF MARKET, BY DOSAGE 111

  • 9.1 OVERVIEW 112
  • 9.2 MONO 115
  • 9.3 COMBINATION 116

10 GLOBAL G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION 117

  • 10.1 OVERVIEW 118
  • 10.2 SUBCUTANEOUS 121
  • 10.3 INTRAVENOUS 122

11 GLOBAL G-CSF/ PEG-G-CSF MARKET, BY PACKAGING 123

  • 11.1 OVERVIEW 124
  • 11.2 PRE FILLED SYRINGES 127
  • 11.3 SINGLE USE VIALS 128

12 GLOBAL G-CSF/ PEG-G-CSF MARKET, BY END USER 129

  • 12.1 OVERVIEW 130
  • 12.2 HOSPITALS AND CLINICS 133
  • 12.3 RESEARCH & ACADEMIC INSTITUTES 133
  • 12.4 AMBULATORY SURGICAL CENTERS 134
  • 12.5 OTHERS 135

13 GLOBAL G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL 136

  • 13.1 OVERVIEW 137
  • 13.2 HOSPITALS PHARMACY 140
  • 13.3 RETAIL PHARMACY 140
  • 13.4 ONLINE PHARMACY 141
  • 13.5 OTHERS 142

14 GLOBAL G-CSF/PEG-G-CSF MARKET, BY REGION 143

  • 14.1 OVERVIEW 144
  • 14.2 EUROPE 149
    • 14.2.1 RUSSIA 156
    • 14.2.2 TURKEY 164
  • 14.3 ASIA-PACIFIC 175
    • 14.3.1 CHINA 182
    • 14.3.2 INDIA 190
    • 14.3.3 INDONESIA 200
    • 14.3.4 THAILAND 208
    • 14.3.5 VIETNAM 215
    • 14.3.6 SINGAPORE 222
    • 14.3.7 PHILIPPINES 230
    • 14.3.8 MALAYSIA 237
  • 14.4 LATIN AMERICA 243
    • 14.4.1 MEXICO 249
    • 14.4.2 COLUMBIA 257
    • 14.4.3 BRAZIL 264
    • 14.4.4 ARGENTINA 272
    • 14.4.5 CHILE 282
    • 14.4.6 PERU 289
    • 14.4.7 ECUADOR 296
  • 14.5 MIDDLE EAST AND AFRICA 304
    • 14.5.1 SOUTH AFRICA 310
    • 14.5.2 SAUDI ARABIA 318
    • 14.5.3 EGYPT 325
    • 14.5.4 ISRAEL 333
    • 14.5.5 UAE 340
    • 14.5.6 KUWAIT 346
    • 14.5.7 OMAN 353

15 GLOBAL G-CSF / PEG-G-CSF MARKET, COMPANY LANDSCAPE 360

  • 15.1 COMPANY SHARE ANALYSIS: GLOBAL 360
  • 15.2 COMPANY SHARE ANALYSIS: EUROPE 361
  • 15.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 362
  • 15.4 COMPANY SHARE ANALYSIS: LATAM 363

16 SWOT ANALYSIS 364

17 COMPANY PROFILE 365

  • 17.1 PFIZER INC. 365
    • 17.1.1 COMPANY SNAPSHOT 365
    • 17.1.2 REVENUE ANALYSIS 366
    • 17.1.3 COMPANY SHARE ANALYSIS 366
    • 17.1.4 PRODUCT PORTFOLIO 367
    • 17.1.5 RECENT DEVELOPMENTS 367
  • 17.2 VIATRIS INC. 368
    • 17.2.1 COMPANY SNAPSHOT 368
    • 17.2.2 REVENUE ANALYSIS 368
    • 17.2.3 COMPANY SHARE ANALYSIS 369
    • 17.2.4 PRODUCT PORTFOLIO 369
    • 17.2.5 RECENT DEVELOPMENT 369
  • 17.3 AMGEN INC. 370
    • 17.3.1 COMPANY SNAPSHOT 370
    • 17.3.2 REVENUE ANALYSIS 370
    • 17.3.3 COMPANY SHARE ANALYSIS 371
    • 17.3.4 PRODUCT PORTFOLIO 371
    • 17.3.5 RECENT DEVELOPMENTS 371
  • 17.4 STADA ARZENEIMITTEL AG 373
    • 17.4.1 COMPANY SNAPSHOT 373
    • 17.4.2 COMPANY SHARE ANALYSIS 373
    • 17.4.3 PRODUCT PORTFOLIO 374
    • 17.4.4 RECENT DEVELOPMENT 374
  • 17.5 TEVA PHARMACEUTICAL INDUSTRIES LTD. 375
    • 17.5.1 COMPANY SNAPSHOT 375
    • 17.5.2 REVENUE ANALYSIS 375
    • 17.5.3 COMPANY SHARE ANALYSIS 376
    • 17.5.4 PRODUCT PORTFOLIO 376
    • 17.5.5 RECENT DEVELOPMENTS 376
  • 17.6 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. 377
    • 17.6.1 COMPANY SNAPSHOT 377
    • 17.6.2 PRODUCT PORTFOLIO 377
    • 17.6.3 RECENT DEVELOPMENTS 377
  • 17.7 ACCORD HEALTHCARE 378
    • 17.7.1 COMPANY SNAPSHOT 378
    • 17.7.2 PRODUCT PORTFOLIO 378
    • 17.7.3 RECENT DEVELOPMENTS 378
  • 17.8 AMNEAL PHARMACEUTICALS LLC. 379
    • 17.8.1 COMPANY SNAPSHOT 379
    • 17.8.2 REVENUE ANALYSIS 379
    • 17.8.3 PRODUCT PORTFOLIO 380
    • 17.8.4 RECENT DEVELOPMENTS 380
  • 17.9 APOTEX INC. 381
    • 17.9.1 COMPANY SNAPSHOT 381
    • 17.9.2 PRODUCT PORTFOLIO 381
    • 17.9.3 RECENT DEVELOPMENT 381
  • 17.10 BIOCON 382
    • 17.10.1 COMPANY SNAPSHOT 382
    • 17.10.2 REVENUE ANALYSIS 382
    • 17.10.3 PRODUCT PORTFOLIO 383
    • 17.10.4 RECENT DEVELOPMENT 383
  • 17.11 BIO SIDUS 384
    • 17.11.1 COMPANY SNAPSHOT 384
    • 17.11.2 PRODUCT PORTFOLIO 384
    • 17.11.3 RECENT DEVELOPMENTS 384
  • 17.12 CADILA PHARMACEUTICALS 385
    • 17.12.1 COMPANY SNAPSHOT 385
    • 17.12.2 PRODUCT PORTFOLIO 385
    • 17.12.3 RECENT DEVELOPMENTS 385
  • 17.13 COHERUS BIOSCIENCES 386
    • 17.13.1 COMPANY SNAPSHOT 386
    • 17.13.2 REVENUE ANALYSIS 386
    • 17.13.3 PRODUCT PORTFOLIO 387
    • 17.13.4 RECENT DEVELOPMENT 387
  • 17.14 DR. REDDY'S LABORATORIES LTD 388
    • 17.14.1 COMPANY SNAPSHOT 388
    • 17.14.2 REVENUE ANALYSIS 388
    • 17.14.3 PRODUCT PORTFOLIO 389
    • 17.14.4 RECENT DEVELOPMENTS 389
  • 17.15 FRESENIUS KABI AG 390
    • 17.15.1 COMPANY SNAPSHOT 390
    • 17.15.2 PRODUCT PORTFOLIO 390
    • 17.15.3 RECENT DEVELOPMENT 390
  • 17.16 GENNOVA BIOPHARMACEUTICALS LIMITED 391
    • 17.16.1 COMPANY SNAPSHOT 391
    • 17.16.2 PRODUCT PORTFOLIO 391
    • 17.16.3 RECENT DEVELOPMENTS 391
  • 17.17 HANGZHOU JIUYUAN GENE ENGINEERING CO., LTD. 392
    • 17.17.1 COMPANY SNAPSHOT 392
    • 17.17.2 PRODUCT PORTFOLIO 392
    • 17.17.3 RECENT DEVELOPMENTS 392
  • 17.18 INTAS PHARMACEUTICALS LTD. 393
    • 17.18.1 COMPANY SNAPSHOT 393
    • 17.18.2 PRODUCT PORTFOLIO 393
    • 17.18.3 RECENT DEVELOPMENT 393
  • 17.19 KASHIV BIOSCIENCES, LLC. 394
    • 17.19.1 COMPANY SNAPSHOT 394
    • 17.19.2 PRODUCT PORTFOLIO 394
    • 17.19.3 RECENT DEVELOPMENT 394
  • 17.20 KYOWA KIRIN CO., LTD. 395
    • 17.20.1 COMPANY SNAPSHOT 395
    • 17.20.2 REVENUE ANALYSIS 395
    • 17.20.3 PRODUCT PORTFOLIO 396
    • 17.20.4 RECENT DEVELOPMENT 396
  • 17.21 LUPIN 397
    • 17.21.1 COMPANY SNAPSHOT 397
    • 17.21.2 REVENUE ANALYSIS 397
    • 17.21.3 PRODUCT PORTFOLIO 398
    • 17.21.4 RECENT DEVELOPMENT 398
  • 17.22 MUNDIPHARMA INTERNATIONAL. 399
    • 17.22.1 COMPANY SNAPSHOT 399
    • 17.22.2 PRODUCT PORTFOLIO 399
    • 17.22.3 RECENT DEVELOPMENT 399
  • 17.23 NAPP PHARMACEUTICALS LIMITED 400
    • 17.23.1 COMPANY SNAPSHOT 400
    • 17.23.2 PRODUCT PORTFOLIO 400
    • 17.23.3 RECENT DEVELOPMENT 400
  • 17.24 RELIANCE LIFE SCIENCES 401
    • 17.24.1 COMPANY SNAPSHOT 401
    • 17.24.2 PRODUCT PORTFOLIO 401
    • 17.24.3 RECENT DEVELOPMENTS 401
  • 17.25 SANDOZ INTERNATIONAL GMBH 402
    • 17.25.1 COMPANY SNAPSHOT 402
    • 17.25.2 REVENUE ANALYSIS 402
    • 17.25.3 PRODUCT PORTFOLIO 403
    • 17.25.4 RECENT DEVELOPMENTS 403
  • 17.26 SPECTRUM PHARMACEUTICALS, INC. 404
    • 17.26.1 COMPANY SNAPSHOT 404
    • 17.26.2 PRODUCT PORTFOLIO 404
    • 17.26.3 RECENT DEVELOPMENT 404
  • 17.27 USV PRIVATE LIMITED 405
    • 17.27.1 COMPANY SNAPSHOT 405
    • 17.27.2 PRODUCT PORTFOLIO 405
    • 17.27.3 RECENT DEVELOPMENTS 405

18 QUESTIONNAIRE 406

19 RELATED REPORTS 409

LIST OF TABLES

  • TABLE 1 BELOW ARE THE RULES AND REGULATIONS TO GET APPROVAL FOR USE IN THE MARKET: 87
  • TABLE 2 GLOBAL G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 104
  • TABLE 3 GLOBAL NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 105
  • TABLE 4 GLOBAL NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 105
  • TABLE 5 GLOBAL ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 107
  • TABLE 6 GLOBAL ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 107
  • TABLE 7 GLOBAL CHRONIC AND AUTO IMMUNE DISEASES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 108
  • TABLE 8 GLOBAL BLOOD DISORDERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 109
  • TABLE 9 GLOBAL GROWTH HORMONE DEFICIENCY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 109
  • TABLE 10 GLOBAL OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 110
  • TABLE 11 GLOBAL G-CSF/ PEG-G-CSF MARKET, BY DOSAGE, 2020-2029 (USD MILLION) 114
  • TABLE 12 GLOBAL MONO IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 115
  • TABLE 13 GLOBAL COMBINATION IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 116
  • TABLE 14 GLOBAL G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 120
  • TABLE 15 GLOBAL SUBCUTANEOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 121
  • TABLE 16 GLOBAL INTRAVENOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 122
  • TABLE 17 GLOBAL G-CSF/ PEG-G-CSF MARKET, BY PACKAGING, 2020-2029 (USD MILLION) 126
  • TABLE 18 GLOBAL PRE FILLED SYRINGES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 127
  • TABLE 19 GLOBAL SINGLE USE VIALS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 128
  • TABLE 20 GLOBAL G-CSF/ PEG-G-CSF MARKET, BY END USER, 2020-2029 (USD MILLION) 132
  • TABLE 21 GLOBAL HOSPITALS AND CLINICS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 133
  • TABLE 22 GLOBAL RESEARCH & ACADEMIC INSTITUTES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 134
  • TABLE 23 GLOBAL AMBULATORY SURGICAL CENTERS IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION) 134
  • TABLE 24 GLOBAL OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 135
  • TABLE 25 GLOBAL G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 139
  • TABLE 26 GLOBAL HOSPITALS PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 140
  • TABLE 27 GLOBAL RETAIL PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 141
  • TABLE 28 GLOBAL ONLINE PHARMACY IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION) 141
  • TABLE 29 GLOBAL OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 142
  • TABLE 30 GLOBAL G-CSF/PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD THOUSAND) 148
  • TABLE 31 EUROPE G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION) 152
  • TABLE 32 EUROPE G-CSF / PEG-G-CSF MARKET, BY COUNTRY, 2020-2030 (USD MILLION) 152
  • TABLE 33 EUROPE G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 153
  • TABLE 34 EUROPE NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 153
  • TABLE 35 EUROPE ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 153
  • TABLE 36 EUROPE G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 154
  • TABLE 37 EUROPE G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 154
  • TABLE 38 EUROPE G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 154
  • TABLE 39 EUROPE G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 154
  • TABLE 40 EUROPE G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 155
  • TABLE 41 RUSSIA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 156
  • TABLE 42 RUSSIA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 156
  • TABLE 43 RUSSIA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 157
  • TABLE 44 RUSSIA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 157
  • TABLE 45 RUSSIA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 157
  • TABLE 46 RUSSIA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 157
  • TABLE 47 RUSSIA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 157
  • TABLE 48 RUSSIA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 158
  • TABLE 49 RUSSIA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 158
  • TABLE 50 RUSSIA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 158
  • TABLE 51 RUSSIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 158
  • TABLE 52 RUSSIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 159
  • TABLE 53 RUSSIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 159
  • TABLE 54 RUSSIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 159
  • TABLE 55 RUSSIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 159
  • TABLE 56 RUSSIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 160
  • TABLE 57 RUSSIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 160
  • TABLE 58 RUSSIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 160
  • TABLE 59 RUSSIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 160
  • TABLE 60 RUSSIA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 161
  • TABLE 61 RUSSIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 161
  • TABLE 62 RUSSIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 161
  • TABLE 63 RUSSIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 161
  • TABLE 64 RUSSIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 162
  • TABLE 65 RUSSIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 162
  • TABLE 66 RUSSIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 162
  • TABLE 67 RUSSIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 162
  • TABLE 68 RUSSIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 163
  • TABLE 69 RUSSIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 163
  • TABLE 70 TURKEY G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 164
  • TABLE 71 TURKEY NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 164
  • TABLE 72 TURKEY ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 165
  • TABLE 73 TURKEY G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 165
  • TABLE 74 TURKEY MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 165
  • TABLE 75 TURKEY G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 165
  • TABLE 76 TURKEY SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 166
  • TABLE 77 TURKEY INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 166
  • TABLE 78 TURKEY G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 166
  • TABLE 79 TURKEY PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 167
  • TABLE 80 TURKEY SINGLE USE VIALS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 167
  • TABLE 81 TURKEY G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 167
  • TABLE 82 TURKEY HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 168
  • TABLE 83 TURKEY HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 168
  • TABLE 84 TURKEY HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 168
  • TABLE 85 TURKEY RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 169
  • TABLE 86 TURKEY RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 169
  • TABLE 87 TURKEY RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 169
  • TABLE 88 TURKEY AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 170
  • TABLE 89 TURKEY AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 170
  • TABLE 90 TURKEY AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 170
  • TABLE 91 TURKEY G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 171
  • TABLE 92 TURKEY HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 171
  • TABLE 93 TURKEY HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 171
  • TABLE 94 TURKEY HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 172
  • TABLE 95 TURKEY RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 172
  • TABLE 96 TURKEY RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 172
  • TABLE 97 TURKEY RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 173
  • TABLE 98 TURKEY ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 173
  • TABLE 99 TURKEY ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 173
  • TABLE 100 TURKEY ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 174
  • TABLE 101 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION) 178
  • TABLE 102 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION) 178
  • TABLE 103 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY COUNTRY, 2020-2030 (USD MILLION) 178
  • TABLE 104 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 179
  • TABLE 105 ASIA-PACIFIC NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 179
  • TABLE 106 ASIA-PACIFIC ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 179
  • TABLE 107 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 180
  • TABLE 108 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 180
  • TABLE 109 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 180
  • TABLE 110 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 180
  • TABLE 111 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 181
  • TABLE 112 CHINA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 182
  • TABLE 113 CHINA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 182
  • TABLE 114 CHINA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 183
  • TABLE 115 CHINA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 183
  • TABLE 116 CHINA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 183
  • TABLE 117 CHINA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 183
  • TABLE 118 CHINA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 184
  • TABLE 119 CHINA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 184
  • TABLE 120 CHINA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 184
  • TABLE 121 CHINA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 185
  • TABLE 122 CHINA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 185
  • TABLE 123 CHINA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 185
  • TABLE 124 CHINA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 186
  • TABLE 125 CHINA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 186
  • TABLE 126 CHINA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 186
  • TABLE 127 CHINA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 186
  • TABLE 128 CHINA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 186
  • TABLE 129 CHINA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 187
  • TABLE 130 CHINA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 187
  • TABLE 131 CHINA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 187
  • TABLE 132 CHINA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 187
  • TABLE 133 CHINA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 188
  • TABLE 134 CHINA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 188
  • TABLE 135 CHINA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 188
  • TABLE 136 CHINA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 188
  • TABLE 137 CHINA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 189
  • TABLE 138 CHINA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 189
  • TABLE 139 INDIA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 190
  • TABLE 140 INDIA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 190
  • TABLE 141 INDIA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 191
  • TABLE 142 INDIA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 191
  • TABLE 143 INDIA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 191
  • TABLE 144 INDIA COMBINATION IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 191
  • TABLE 145 INDIA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 192
  • TABLE 146 INDIA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 192
  • TABLE 147 INDIA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 192
  • TABLE 148 INDIA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 192
  • TABLE 149 INDIA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 193
  • TABLE 150 INDIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 193
  • TABLE 151 INDIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 193
  • TABLE 152 INDIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 194
  • TABLE 153 INDIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 194
  • TABLE 154 INDIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 194

LIST OF FIGURES

  • FIGURE 1 GLOBAL G-CSF / PEG-G-CSF MARKET: SEGMENTATION 56
  • FIGURE 2 GLOBAL G-CSF / PEG-G-CSF MARKET: DATA TRIANGULATION 59
  • FIGURE 3 GLOBAL G-CSF / PEG-G-CSF MARKET: DROC ANALYSIS 60
  • FIGURE 4 GLOBAL G-CSF / PEG-G-CSF MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 61
  • FIGURE 5 GLOBAL G-CSF / PEG-G-CSF MARKET: COMPANY RESEARCH ANALYSIS 61
  • FIGURE 6 GLOBAL G-CSF / PEG-G-CSF MARKET: INTERVIEW DEMOGRAPHICS 63
  • FIGURE 7 GLOBAL G-CSF / PEG-G-CSF MARKET: DBMR MARKET POSITION GRID 64
  • FIGURE 8 GLOBAL G-CSF / PEG-G-CSF MARKET: MARKET END USER COVERAGE GRID 65
  • FIGURE 9 GLOBAL G-CSF / PEG-G-CSF MARKET: VENDOR SHARE ANALYSIS 66
  • FIGURE 10 GLOBAL G-CSF / PEG-G-CSF MARKET: SEGMENTATION 70
  • FIGURE 11 THE INCREASE IN CANCER PROPHYLAXIS IN DEVELOPED COUNTRIES AND INITIATIVES TAKEN BY GOVERNMENTS ARE TO DRIVE THE GLOBAL G-CSF / PEG-G-CSF MARKET FROM 2023 TO 2030 71
  • FIGURE 12 NEUTROPENIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL G-CSF / PEG-G-CSF MARKET IN 2023 & 2030 71
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL G-CSF / PEG-G-CSF MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 72
  • FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR G-CSF / PEG-G-CSF MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 73
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL G-CSF / PEG-G-CSF MARKET 91
  • FIGURE 16 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, 2022 102
  • FIGURE 17 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, 2021-2030 (USD MILLION) 103
  • FIGURE 18 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, CAGR (2022-2029) 103
  • FIGURE 19 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, LIFELINE CURVE 104
  • FIGURE 20 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, 2022 112
  • FIGURE 21 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, 2021-2030 (USD MILLION) 113
  • FIGURE 22 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, CAGR (2023-2030) 113
  • FIGURE 23 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, LIFELINE CURVE 114
  • FIGURE 24 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, 2022 118
  • FIGURE 25 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION) 119
  • FIGURE 26 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 119
  • FIGURE 27 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 120
  • FIGURE 28 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, 2022 124
  • FIGURE 29 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, 2021-2030 (USD MILLION) 125
  • FIGURE 30 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, CAGR (2023-2030) 125
  • FIGURE 31 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, LIFELINE CURVE 126
  • FIGURE 32 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY END USER, 2022 130
  • FIGURE 33 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY END USER, 2021-2030 (USD MILLION) 131
  • FIGURE 34 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY END USER, CAGR (2023-2030) 131
  • FIGURE 35 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY END USER, LIFELINE CURVE 132
  • FIGURE 36 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, 2022 137
  • FIGURE 37 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 138
  • FIGURE 38 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 138
  • FIGURE 39 GLOBAL G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 139
  • FIGURE 40 GLOBAL G-CSF/PEG-G-CSF MARKET: SNAPSHOT (2022) 145
  • FIGURE 41 GLOBAL G-CSF/PEG-G-CSF MARKET: BY REGION (2022) 146
  • FIGURE 42 GLOBAL G-CSF/PEG-G-CSF MARKET: BY REGION (2022 & 2030) 146
  • FIGURE 43 GLOBAL G-CSF/PEG-G-CSF MARKET: BY REGION (2022 & 2030) 147
  • FIGURE 44 GLOBAL G-CSF/PEG-G-CSF MARKET: BY INDICATION (2023-2030) 147
  • FIGURE 45 EUROPE G-CSF/PEG-G-CSF MARKET: SNAPSHOT (2022) 149
  • FIGURE 46 EUROPE G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022) 150
  • FIGURE 47 EUROPE G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030) 150
  • FIGURE 48 EUROPE G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030) 151
  • FIGURE 49 EUROPE G-CSF/PEG-G-CSF MARKET: BY INDICATION (2023-2030) 151
  • FIGURE 50 ASIA-PACIFIC G-CSF/PEG-G-CSF MARKET: SNAPSHOT (2022) 175
  • FIGURE 51 ASIA-PACIFIC G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022) 176
  • FIGURE 52 ASIA-PACIFIC G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030) 176
  • FIGURE 53 ASIA-PACIFIC G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030) 177
  • FIGURE 54 ASIA-PACIFIC G-CSF/PEG-G-CSF MARKET: BY INDICATION (2023-2030) 177
  • FIGURE 55 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: SNAPSHOT (2022) 243
  • FIGURE 56 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022) 244
  • FIGURE 57 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030) 244
  • FIGURE 58 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030) 245
  • FIGURE 59 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: BY INDICATION (2023-2030) 245
  • FIGURE 60 MIDDLE EAST AND AFRICA G-CSF/PEG-G-CSF MARKET: SNAPSHOT (2022) 304
  • FIGURE 61 MIDDLE EAST AND AFRICA G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022) 305
  • FIGURE 62 MIDDLE EAST AND AFRICA G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030) 305
  • FIGURE 63 MIDDLE EAST AND AFRICA G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030) 306
  • FIGURE 64 MIDDLE EAST AND AFRICA G-CSF/PEG-G-CSF MARKET: BY INDICATION (2023-2030) 306
  • FIGURE 65 GLOBAL G-CSF / PEG-G-CSF MARKET: COMPANY SHARE 2022 (%) 360
  • FIGURE 66 EUROPE G-CSF / PEG-G-CSF MARKET: COMPANY SHARE 2022 (%) 361
  • FIGURE 67 ASIA-PACIFIC G-CSF / PEG-G-CSF MARKET: COMPANY SHARE 2022 (%) 362
  • FIGURE 68 LATAM G-CSF / PEG-G-CSF MARKET: COMPANY SHARE 2022 (%) 363
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!